• Home
  • Events
  • Monday Lunch Livestream: Improving patient responses to immunotherapy
Back to all events
12 Dec 2022
  • Peter MacCallum Cancer Centre
  • VCCC Alliance
Monday Lunch Livestream | Webinar | 1.00–2.00PM

Monday Lunch Livestream: Improving patient responses to immunotherapy

Immunotherapies take advantage of our immune system to fight cancer and have revolutionised modern cancer treatment.

Associate Professor Jane Oliaro
presents us with research aimed at discovering new therapeutic targets to improve patient responses to immunotherapies.

A limitation to immunotherapy approaches is that the immune response can vary widely depending on the cancer type. This leads to variation in the proportion of patients who respond positively to immunotherapy. Furthermore, intrinsic or acquired genetic mutations can determine the sensitivity or resistance of tumours to immunotherapy approaches such as checkpoint blockade and adoptive cell therapy.

Associate Professor Oliaro will provide us with CRISPR-based genetic screening approaches to uncover mechanisms of tumour immune evasion.

The results of her lab's work highlight a role for tumour necrosis factor (TNF)-mediated bystander killing as a potent immune cell effector mechanism. The data generated also identifies new genes and pathways that may predict response to checkpoint blockade, or be therapeutically targeted to improve the number of patients that benefit from immunotherapy. 


Associate Professor Jane Oliaro
Peter MacCallum Cancer Centre

Associate Professor Jane Oliaro is a Group Leader in the Cancer Immunology Program and Chief Scientist for the Centre of Excellence in Cellular Immunotherapy Translation Laboratory at the Peter MacCallum Cancer Centre.

Jane completed a BSc (Hons) at Monash University in Melbourne, a PhD at Massey University in New Zealand, followed by postdoctoral training in France (INSERM, Montpellier) and Australia (Peter MacCallum).

Jane’s research program uses a range of immune-based assays, genetic screening and preclinical models to dissect the complex interplay between the immune system and cancer, with a particular focus on tumor immune evasion and resistance to immunotherapies such as checkpoint blockade and CAR-T cell therapy.

Monday 12 December
Get the latest in cancer news, events and more, direct to your inbox
Join a network of Victorian cancer researchers, clinicians and consumers to keep your finger on the pulse.